Mergers and acquisitions in any market can define the landscape for its players. In this article, Emma Danks of Taylor Wessing reflects on recent M&A activity in the biopharmaceutical industry, highlighting influencing trends and what this might mean for the future.
The current state of the M&A market
THE LAST 12 months have demonstrated a strong mergers and acquisitions (M&A) trend, particularly in the US and China. We have also seen the emergence of cross-sector deals, largely a result of acquisitions by tech-backed investors – even giants like Amazon and Google are getting in on the game.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Many of these deals have been driven by the blurring lines between technology and healthcare, with the ongoing entry of consumer-focused digital companies into the life sciences market.
Traditional business models are being challenged, causing businesses to look for new sources of growth in an increasingly patient-centric and digitally-enabled world. Overlaid with this is a focus on restructuring portfolios and divestments, driven by specialisations in a fragmented therapeutic marketplace.
However, in the context of a changing economic landscape and an uncertain political future, the result has been a recent downturn in M&A in recent months. The dreaded ‘B word’ looms large in the UK, which might account for a lack of higher profile deals in H1 2019. In the US, we are also seeing a rise in protectionist trade policies leading to a slowdown in cross-border M&A. Added to this, we have had five years of unprecedented market liquidity with many startups (especially biotech companies developing curative or genetic therapies) being so well capitalised that they are under no immediate pressure to be acquired.
The IP differentiator
The life sciences sector is underpinned by intellectual property (IP) rights and, in particular, a company’s ability, as a result of its intellectual property assets, to prevent others from competing with its products. The enormous investment required to bring a product to market simply would not be worth pursuing if a period of exclusivity (or at least restricted market access) was not available; consequently, to an extent, all deals in the life sciences sector are driven by intellectual property. Much of the acquisition strategy of the life sciences majors has been around targeted acquisitions of companies with intellectual property assets and product pipelines (or, alternatively, portfolios of such assets) that align with their strategic areas of therapeutic focus.
The enormous investment required to bring a product to market simply would not be worth pursuing if a period of exclusivity (or at least restricted market access) was not available”
However, the divergence in M&A strategy between patented products and the generics pharmaceutical sector is marked.
The increased level of M&A activity in the generics pharmaceutical sector is driven by the relative lack of intellectual property rights in the products these companies market. Accordingly, M&A activity arises from a need to create alternative barriers to competition by creating economies of scale and a more comprehensive offering in their chosen area of therapeutic focus.
Portfolio and divestment restructuring
Divestments play a vital part in rebalancing portfolios, as they allow companies to exit de‑prioritised areas so that they can devote more attention to core fields. Recent figures suggest that many life sciences companies plan to divest a substantial part of their businesses. For example, GlaxoSmithKline (GSK) intends to split into two companies within the next two years – one focused on consumer health and one focused on developing and commercialising innovative drugs.
A combination of factors is driving this decision; firstly, the importance of specialisation in a fragmented therapeutic marketplace. Secondly, the classic business model is changing as the medical community and patients demand more cost effective and efficient care that utilises new digital platforms. Studies also show that more focused business models typically out-perform less focused ones.
Such activity can also be part of a wider M&A strategy to complement a rebalanced portfolio. Alternatively, particularly given the M&A activity in the generics pharmaceutical sector, follow-on M&A deals are precipitated by anti-trust necessity following merger activity (eg, post the Allergan generics business acquisition by Teva in 2015). Anti-trust regulators are becoming tougher and imposing more conditions on M&A transactions. Shareholder activism has also risen in prominence over the last few years and investor pressure is often cited as a reason to divest.
Finally, diversified conglomerates with healthcare assets are optimising their portfolios. For instance, Siemens floated a 15 percent stake in its medical imaging and diagnostics division.
The rise of cross-sector deals
The boundaries of healthcare and technology continue to merge. Many life sciences companies are facing significant challenges to their typical business models, particularly as a result of the recent and ongoing entry of consumer-focused digital companies into healthcare. These companies can use their connected devices, data analytics skills and deep consumer relationships to progress further – for example, Apple’s newest watch incorporates an electrical heart-rate sensor that can take an ECG using an app, which has FDA approval. Alphabet Inc (part of Google) has continued investing in life sciences companies and Amazon recently acquired Pillpack, Inc. (a pharmacy delivering medications packaged in pre-sorted doses, which holds pharmacy licences in all 50 states in the US).
Institutional interest
Private equity investors have generally been reluctant to invest in the pharmaceutical sector and/or drug development, as it is a costly and lengthy endeavour (which conflicts with their typical hold period of three-to-five years) with a reasonably high level of risk, in contrast to other sectors where private equity typically invests. However, several strong fundraising years mean that the funds now have cash to spend and are considering the pharma space in a new light, as well as the medtech/ healthcare sectors, as viable investment opportunities.
The future
Divestitures and spinouts will continue, and market fragmentation will remain a key driver of deals. Fragmentation is apparent across multiple individual therapeutic areas, especially oncology, which is the largest and fastest growing therapeutic area and continues to be a lynchpin of M&A activity.
Many life sciences companies are facing significant challenges to their typical business models”
M&A activity, as we have traditionally seen it in life sciences and healthcare, is likely to be more moderate as the typical business model continues to be challenged by tech players in the market. This might alter the drivers of success, with big data and analytics capabilities being the critical determining factors in the future, rather than a company’s biological and chemical competencies in creating novel drugs and devices.
A tighter focus on a company’s core business, especially through purpose-driven divestment, as the cornerstone of any M&A activity, will be something to always keep in mind. Portfolio reviews will also be a strategic priority and one of the best paths to sustained growth. As the life sciences sector becomes ever more patient-centric and the market continues to overlap with technology, it will be those companies able to exploit that convergence that will be the most successful.
About the author
Emma Danks is partner and head of the private equity group at international law firm Taylor Wessing LLP. She has advised UK and international private equity houses and their investee companies on a wide range of leveraged buy-outs and related transactions. Emma is also well-known for her expertise in advising management teams on buy-out transactions.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.